CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies. Its lead drug candidate is Aldoxorubicin, an improved version of anti-cancer drug doxorubicin out-licensed to NantCell, Inc. Aldoxorubicin is in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, as well as evaluating in various other cancer indications with unmet clinical need, including small-cell lung cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYTR
CUSIPN/A
Phone310-826-5648
Debt
Debt-to-Equity RatioN/A
Current Ratio1.92
Quick Ratio1.92
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$100,000.00
Price / Sales407.04
Cash FlowN/A
Price / CashN/A
Book Value$0.66 per share
Price / Book1.83
Profitability
EPS (Most Recent Fiscal Year)($1.52)
Net Income$-34,980,000.00
Net MarginsN/A
Return on Equity-137.27%
Return on Assets-55.06%
Miscellaneous
Employees20
Outstanding Shares33,640,000
Market Cap$41.37
CytRx (NASDAQ:CYTR) Frequently Asked Questions
What is CytRx's stock symbol?
CytRx trades on the NASDAQ under the ticker symbol "CYTR."
When did CytRx's stock split? How did CytRx's stock split work?
Shares of CytRx reverse split on Wednesday, November 1st 2017. The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 31st 2017. An investor that had 100 shares of CytRx stock prior to the reverse split would have 17 shares after the split.
How were CytRx's earnings last quarter?
CytRx Co. (NASDAQ:CYTR) issued its quarterly earnings data on Friday, May, 11th. The biotechnology company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.09. View CytRx's Earnings History.
When is CytRx's next earnings date?
What price target have analysts set for CYTR?
1 Wall Street analysts have issued 12 month target prices for CytRx's shares. Their predictions range from $5.00 to $5.00. On average, they anticipate CytRx's stock price to reach $5.00 in the next year. This suggests a possible upside of 313.2% from the stock's current price. View Analyst Ratings for CytRx.
What is the consensus analysts' recommendation for CytRx?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytRx in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of CytRx's key competitors?
Some companies that are related to CytRx include Organovo (ONVO), Pluristem Therapeutics (PSTI), Cidara Therapeutics (CDTX), Eiger Biopharmaceuticals (EIGR), Aptose Biosciences (APTO), Champions Oncology (CSBR), Brainstorm Cell Therapeutics (BCLI), Applied Genetic Technologies (AGTC), Entera Bio (ENTX), Genocea Biosciences (GNCA), Curis (CRIS), BioCardia (BCDA), Aevi Genomic Medicine (GNMX), TRACON Pharmaceuticals (TCON) and Arsanis (ASNS).
Who are CytRx's key executives?
CytRx's management team includes the folowing people:
- Mr. Steven A. Kriegsman, Chairman & CEO (Age 76)
- Mr. John Y. Caloz, Chief Financial Officer (Age 66)
- Mr. Eric L. Curtis, Pres & COO
- Dr. Felix Kratz Ph.D., Sr. VP, Drug Devel. (Age 55)
- Dr. André Warnecke Ph.D., Sr. Director of Drug Discovery
Has CytRx been receiving favorable news coverage?
Headlines about CYTR stock have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. CytRx earned a media sentiment score of 0.02 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 46.87 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are CytRx's major shareholders?
How do I buy shares of CytRx?
Shares of CYTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CytRx's stock price today?
One share of CYTR stock can currently be purchased for approximately $1.21.
How big of a company is CytRx?
CytRx has a market capitalization of $41.37 million and generates $100,000.00 in revenue each year. The biotechnology company earns $-34,980,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. CytRx employs 20 workers across the globe.
How can I contact CytRx?
CytRx's mailing address is 11726 SAN VICENTE BOULEVARD SUITE 650, LOS ANGELES CA, 90049. The biotechnology company can be reached via phone at 310-826-5648 or via email at [email protected]
MarketBeat Community Rating for CytRx (NASDAQ CYTR)
MarketBeat's community ratings are surveys of what our community members think about CytRx and other stocks. Vote "Outperform" if you believe CYTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
